Chu Brest Hopital Morvan

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Metastatic breast cancer2 trials
• Atopic dermatitis (eczema)1 trial
• Childhood cancers1 trial
• Glioblastoma1 trial
• Haemophilia1 trial
• Lung cancer1 trial
• Osteoporosis1 trial
• Prostate cancer1 trial
• Sarcoma1 trial
• Stroke1 trial

Phase

• Phase 36 trials

Status

• Completed5 trials
• Recruiting3 trials
• Not yet recruiting1 trial

Lead sponsor

• Daiichi Sankyo2 trials
• Pfizer2 trials
• Centre Hospitalier Universitaire de Saint Etienne1 trial
• EMD Serono Research & Development Institute, Inc.1 trial
• Gustave Roussy, Cancer Campus, Grand Paris1 trial
• and 2 more

Running trials

• Recruiting

  Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse

  NCT07871864· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

  Contact: Liana CARAUSU, Dr

• Recruiting

  TTFields General Routine Clinical Care in ndGBM Patients: a French Prospective Non-Interventional Study (TIGER France)

  NCT06924099· NovoCure Ltd.· Source

  Contact: CHU BREST HOPITAL MORVAN

• Recruiting

  A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.

  NCT05689151· Pfizer· Source

• Recruiting

  High Dose Steroids in Children With Stroke

  NCT04873583· Phase 3· Insel Gruppe AG, University Hospital Bern· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atopic dermatitis (eczema)1 recruiting
• Childhood cancers1 recruiting
• Glioblastoma1 recruiting
• Sarcoma1 recruiting
• Stroke1 recruiting

Closed trials

• Completed

  Haemophilia and Bone Loss - PHILEOS Study

  NCT04384341· Centre Hospitalier Universitaire de Saint Etienne· Source

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Daiichi Sankyo· Source

• Completed

  DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

  NCT03523585· Phase 3· Daiichi Sankyo· Source

• Completed

  Avelumab in First-line NSCLC (JAVELIN Lung 100)

  NCT02576574· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· Phase 3· Pfizer· Source